

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A pharmaceutical liquid suspension dosage form comprising:
 - a) particles of an NSAID and/or acetaminophen, wherein at least 99% of said particles are covered with one layer of a controlled release composition wherein said controlled release composition ~~is~~ comprises of an insoluble film forming polymer and an enteric polymer, wherein the weight ratio of the insoluble film forming polymer and the enteric polymer is from about 80:20 to about 99:1 and wherein the average diameter of said particles is from about 20 to about 400 microns, and
 - b) a vehicle for the administration of the particles comprising water, wherein the pharmaceutical liquid suspension dosage form has a duration of therapeutic effect for at least 8 hours after its initial administration to a mammal.
2. (Cancelled).
3. (Previously Presented) The dosage form of claim 1, wherein the vehicle further comprises one or more agents selected from the group consisting of suspending systems, surfactants, sweeteners, buffering agents, preservatives, flavoring agents, and mixtures thereof.
4. (Previously Presented) The dosage form of claim 1, wherein the vehicle further comprises a pharmaceutically acceptable water-miscible co-solvent selected from the group consisting of glycols, alcohols, and glycerol.
5. (Original) The dosage form of claim 1, wherein said particles are comprised of a core that is substantially covered by the controlled release composition.
6. (Previously Presented) The dosage form of claim 5, wherein said controlled release composition is comprised of, based upon the total dry weight of the coating, between_0

percent and 100 percent of the insoluble film forming polymer and from 0 percent to 10 percent of the enteric polymer.

7. (Cancelled)

8. (Cancelled)

9. (Previously Presented) The dosage form of claim 6, wherein the insoluble film forming polymer is selected from the group consisting of cellulose acetate, ethylcellulose, poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) in a 1:2:0.1 weight ratio, and copolymers and mixtures thereof.

10. (Previously Presented) The dosage form of claim 6, wherein the enteric polymer is selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, polyvinylacetate phthalate, polymethacrylate-based polymers, and copolymers and mixtures thereof.

11. (Original) The dosage form of claim 10, wherein the polymethacrylate-based polymer is poly(methacrylic acid, methyl methacrylate) in a weight ratio of 1:2 and/or poly(methacrylic acid, methyl methacrylate) in a weight ratio of 1:1.

12. (Original) The dosage form of claim 5 wherein the coated particles are comprised of, based upon the total dry weight of the coated particles, from about 10 percent to about 40 percent of the controlled release composition.

13. (Original) The dosage form of claim 1, wherein said therapeutic effect is pain relief.

14. (Previously Presented) The dosage form of claim 1, wherein the NSAID is selected from the group consisting of ibuprofen, naproxen, and ketoprofen.

15. (Previously Presented) A method for treating pain in a mammal in need thereof, which comprises administering the dosage form of claim 1 in an amount effective for providing pain relief to the mammal for a period of at least 12 hours after administration of the dosage form.

16. (Cancelled)

17. (Previously Presented) The dosage form of claim 1 wherein the dosage form comprises, based upon the total weight of the dosage form:

a) from about 0.05 percent to about 40 percent of the particles containing NSAID and/or acetaminophen; and

b) from about 20 percent to about 70 percent of the water, or mixtures of the water and a pharmaceutically acceptable water-miscible co-solvent selected from the group consisting of glycols, alcohols, and glycerol,

wherein the dosage form has a duration of therapeutic effect for at least 8 hours after its administration.

18. (Previously Presented) A method for treating pain in a mammal in need thereof, which comprises administering the dosage form of claim 17 in an amount effective for providing pain relief to the mammal for a period of at least 12 hours after administration of the dosage form.

19. (Previously Presented) A method of administering acetaminophen and/or an NSAID in a liquid suspension pharmaceutical dosage form to a mammal in need thereof, said method comprises providing to a mammal a dosage form of claim 1 such that the mammal receives a controlled release dose of said acetaminophen and/or NSAID over a period of about 12 hours after administration of said dosage form, wherein no further acetaminophen and/or NSAID is provided during said 12 hour time period.

20. (Currently Amended) A pharmaceutical liquid suspension dosage form comprising:

a) particles containing NSAID and/or acetaminophen, said particles wherein at least 99% of said particles are covered with one layer of a controlled release composition, said controlled release composition being comprised of, based upon the total weight of the controlled release composition, between 0 percent and 90 percent of an insoluble film forming polymer and between 0 percent and 10 percent of an enteric polymer, wherein the weight ratio of the insoluble film forming polymer and the enteric polymer is from about 80:20 to about 99:1 and wherein the average diameter of said particles is from about 20 to about 400 microns; and

b) water, or mixtures of water and a pharmaceutically acceptable water-miscible co-solvent selected from the group consisting of glycols, alcohols, and glycerol,

wherein the pharmaceutical dosage form has a duration of therapeutic effect for at least 12 hours after its administration.

21. (Previously Presented) The dosage form of claim 20, wherein the dosage form comprises, based upon a total weight of the dosage form:

a) from about 0.05 percent to about 40 percent of the particles; and

b) from about 20 percent to about 70 percent of the water, or mixtures of water and a pharmaceutically acceptable water-miscible co-solvent selected from the group consisting of glycols, alcohols, and glycerol,

wherein the dosage form has a duration of therapeutic effect for at least 12 hours after its administration.

22. (Cancelled)

23. (Cancelled)

24. (Previously Presented) The dosage form of claim 1, wherein the insoluble film forming polymer is selected from the group consisting of cellulose acetate, ethylcellulose, poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) in a 1:2:0.1 weight ratio, and copolymers and mixtures thereof.

25. (Previously Presented) The dosage form of claim 1, wherein the enteric polymer is selected from the group consisting of hydroxypropyl methylcellulose phthalate,

hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, polyvinylacetate phthalate, polymethacrylate-based polymers, and copolymers and mixtures thereof.

26. (Previously Presented) The dosage form of claim 24, wherein the enteric polymer is selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, polyvinylacetate phthalate, polymethacrylate-based polymers, and copolymers and mixtures thereof.

27. (Previously Presented) The dosage form of claim 6, wherein the NSAID is selected from the group consisting of ibuprofen, naproxen, and ketoprofen.

28. (Previously Presented) The dosage form of claim 17, wherein the NSAID is selected from the group consisting of ibuprofen, naproxen, and ketoprofen.

29. (Previously Presented) The method of claim 19, wherein the NSAID is selected from the group consisting of ibuprofen, naproxen, and ketoprofen.

30. (Previously Presented) The dosage form of claim 20, wherein the NSAID is selected from the group consisting of ibuprofen, naproxen, and ketoprofen.

31. (New) The dosage form of claim 27, wherein the pKa of said NSAID is greater than the pH of the liquid suspension pharmaceutical dosage form.

32. (New) The dosage form of claim 28, wherein the pKa of said NSAID is greater than the pH of the liquid suspension pharmaceutical dosage form.

33. (New) The dosage form of claim 29, wherein the pKa of said NSAID is greater than the pH of the liquid suspension pharmaceutical dosage form.

Serial No. 10/697,840

34. (New) The dosage form of claim 30, wherein the pKa of said NSAID is greater than the pH of the liquid suspension pharmaceutical dosage form.